InProTher is developing first-in-class immunotherapies against cancer and has pre-clinical proof of concept for broad and curative cancer therapy.
Treated animals eliminate their tumors and become resistant to challenge from administered cancer cells.
A combination with immune checkpoint inhibitors makes the effect complete in animal models. InProTher's research is based upon research by Associate Professor Peter Johannes Holst and colleagues and international collaborators.
Treated animals eliminate their tumors and become resistant to challenge from administered cancer cells.
A combination with immune checkpoint inhibitors makes the effect complete in animal models. InProTher's research is based upon research by Associate Professor Peter Johannes Holst and colleagues and international collaborators.
Location: Denmark
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | SeedFolio | seedfolio.... |
Mentions in press and media 3
| Date | Title | Description |
| 24.05.2023 | InProTher Raises EUR6M in Seed Financing | InProTher, a Copenhagen, Denmark-based early-stage biotechnology company developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), raised EUR 6M Seed funding. Backers included private investors and the Europe... |
| 04.02.2020 | SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV) | Five years of collaborative discovery work comes to fruition MUNICH & COPENHAGEN, Denmark–(BUSINESS WIRE)–February 4, 2020– SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cel... |
| - | InProTher | “InProTher – InProTher treats cancer by target tumor virus within the human genome.” |